

NOV. 18. 2005 3:55PM

GW GLOBAL R&D IS

RECEIVED
CENTRAL FAX CENTER

NO. 0091 P. 1

NOV 18 2005

FAX



To Art Unit 1615

Company USPTO

Fax 571-273-8300

From Valerie L. Phillips

Tel 919-483-8223 Fax 919-483-5730

E-mail Vlp47157@gsk.com

Date November 18, 2005 Pages including cover 7

Subject Request For Corrected Filing Receipt

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Serial No.: 10/524,462

Date: October 18, 2005

Applicant: Weingarten et al.

Title: Pyrimidine Derivative As Selective COX-2 Inhibitors

Attached:

Request for Corrected Filing Receipt w/Certificate of transmission via facsimile
Filing Receipt (copy)

Thank you,
Valerie Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

NOV. 18. 2005 3:55PM

GW GLOBAL R&D IS

RECEIVED
CENTRAL FAX CENTER NO. 0091 P. 2

PG4894USW

NOV 18 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weingarten et al.
Serial No.: 10/524.462 Art Unit: 1615
Filed: October 18, 2005 Examiner:
For: Pyrimidine Derivative As Selective COX-2 Inhibitors

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.
2. There is an error with respect to the following data, which is:
- 3.

☒ incorrectly entered

and/or

☐ omitted.


Error in

1. ☐ Applnt's name:
2. ☐ Applicant's address:
3. ☐ Title
4. ☐ Filing date
5. ☐ Serial Number
6. ☐ Foreign Applications
7. ☒ Other --: Total Claims 15

Correct data

- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
7. Total Claims 19

4. Charge Account 07-1392 for any fees which may be due.


J. Scott Young

Registration No.: 45,582

Date:
GlaxoSmithKline
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Phone: 919-483-8160
Fax: 919-483-7988

CERTIFICATE OF MAILING/TRANSMISSION (37 CFR 1.8)

I hereby certify that this correspondence is, on the date shown below, being:


MAILING

☐ deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Date: _____

FACSIMILE

☒ Transmitted by facsimile to the Patent and Trademark Office.


Signature
Valerie L. Phillips



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

COPIED TO THE UK

44M JSY/JRC/val

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/524,462	10/18/2005	1615	1030	PG4894USW		15 19	3

CONFIRMATION NO. 4839

23347


GLAXOSMITHKLINE

CORPORATE INTELLECTUAL PROPERTY, MA 01775

FIVE MOORE DR., PO BOX 13398

RESEARCH TRIANGLE PARK, NC 27709-3398

FILING RECEIPT



C000000017310290*

Date Mailed: 10/24/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Gordon Weingarten, Stevenage, UNITED KINGDOM;
Gianpaolo Bravi, Stevenage, GBN, UNITED KINGDOM;Power of Attorney: The patent practitioners associated with Customer Number 23347.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/09153 08/15/2003

Foreign Applications

UNITED KINGDOM 0219304.3 08/19/2002

UNITED KINGDOM 0219305.0 08/19/2002

Projected Publication Date: 02/02/2006

Non-Publication Request: No

Early Publication Request: No

Title

Pyrimidine derivative as selective cox-2 inhibitors

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.